Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received approval from Japan’s Ministry of Health, Labour …
![Argenx VYVDURA: Japan Approval for Myasthenia Gravis Treatment](https://i0.wp.com/globalpharmalive.com/wp-content/uploads/2024/01/pexels-karolina-grabowska-4210615.jpg?resize=760%2C427&ssl=1)
![Argenx VYVDURA: Japan Approval for Myasthenia Gravis Treatment](https://i0.wp.com/globalpharmalive.com/wp-content/uploads/2024/01/pexels-karolina-grabowska-4210615.jpg?resize=760%2C427&ssl=1)
Pharma News From Around The World
Pharma News From Around The World
Pharma News From Around The World
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received approval from Japan’s Ministry of Health, Labour …
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received European Commission (EC) approval of …